Imigran (Sumatriptan)

Imigran (sumatriptan) is indicated for acute migraine management, acting on the trigeminovascular pathway.

• Acute migraine attack: provides rapid relief of headache and associated nausea.
• Migraine with aura: alleviates pain and visual disturbances during an attack.
• Cluster headache (acute): reduces severity of episodic cluster headache attacks.

• Sumatriptan is a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation of these receptors induces vasoconstriction of intracranial arteries and inhibits release of pro‑inflammatory neuropeptides, thereby interrupting the cascade that generates migraine pain. The drug’s high affinity for these receptor subtypes results in a prompt therapeutic effect when administered nasally, allowing drug absorption through the nasal mucosa into the systemic circulation.

Sumatriptan nasal spray may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Taste disturbance: altered or unpleasant taste after administration.
• Nasal irritation: burning, stinging, or discomfort in the nasal passages.
• Dizziness: feeling light‑headed or unsteady.
• Somnolence: mild sleepiness or fatigue.
• Nausea: mild gastrointestinal upset.
• Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects

• Chest pain: may indicate cardiac ischemia.
• Coronary vasospasm: constriction of coronary arteries.
• Severe hypertension: sudden increase in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, muscle rigidity.
• Allergic reaction: rash, swelling, or difficulty breathing.
• Ischemic events: stroke or transient ischemic attack.

When prescribing Imigran, clinicians should consider several safety precautions to minimize risk.

• Cardiovascular disease: contraindicated in patients with known coronary artery disease or uncontrolled hypertension.
• Hemiplegic or basilar migraine: avoid use due to increased stroke risk.
• Serotonergic agents: caution when combined with SSRIs, SNRIs, or MAO inhibitors.
• Liver impairment: use with caution in moderate hepatic dysfunction.
• Pregnancy and lactation: safety not established; assess risk‑benefit before use.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Sumatriptan can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe serotonin syndrome.
• Other triptans: additive vasoconstrictive effects.
• Ergot alkaloids: increased vasospasm risk.
• SSRIs/SNRIs: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance blood pressure lowering.
• CYP3A4 inhibitors (e.g., ketoconazole): increase sumatriptan plasma levels.
• CYP3A4 inducers (e.g., rifampin): reduce efficacy of sumatriptan.
• Oral contraceptives: may alter hormonal migraine patterns.